- Home
- HUT vs EXEL Comparison
HUT vs EXEL Comparison
Compare HUT & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HUT | EXEL |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 11.4B |
| IPO Year | 2023 | 2000 |
Fundamental Metrics
Financial Performance| Metric | HUT | EXEL |
|---|---|---|
| Price | $120.67 | $54.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $65.20 | $46.50 |
| AVG Volume (30 Days) | ★ 3.7M | 2.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 0.79 |
| Revenue | $235,118,000.00 | ★ $452,477,000.00 |
| Revenue This Year | $161.69 | $13.61 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | ★ N/A | $67.38 |
| Revenue Growth | ★ 44.79 | N/A |
| 52 Week Low | $17.87 | $33.76 |
| 52 Week High | $140.80 | $53.93 |
Technical Indicators
Market Signals| Indicator | HUT | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 65.70 |
| Support Level | $39.84 | $40.17 |
| Resistance Level | $140.80 | N/A |
| Average True Range (ATR) | 10.50 | 1.52 |
| MACD | -1.43 | -0.04 |
| Stochastic Oscillator | 65.55 | 90.23 |
Price Performance
Historical ComparisonAbout HUT Hut 8 Corp.
Hut 8 Corp is an energy infrastructure platform that integrates power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive use cases. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.